Overhauling the Food and Drug Administration (FDA)

The Wall Street Journal reports that Sen. Charles Grassley and Rep.
John Dingell are taking the lead in calling for revamping the FDA which is
recognized as being “too cozy with the companies they regulate.”

“The lawmakers say an FDA restructuring should build a much taller wall
between the agency and the industry it regulates. The FDA would gain
authority to recall drugs, which it can’t do today, and to impose
significant fines on drug companies for safety violations. The lawmakers
also want the FDA to inspect generic-drug makers before approving a new
product. Perhaps most importantly, they want the next president to appoint a
tough FDA commissioner completely independent from the industry.” Read the rest of this entry »